Last $1.35 USD
Change Today +0.06 / 4.65%
Volume 73.9K
PIP On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 2:18 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Open
$1.31
Previous Close
$1.29
Day High
$1.38
Day Low
$1.29
52 Week High
08/26/13 - $2.42
52 Week Low
07/23/14 - $1.19
Market Cap
73.6M
Average Volume 10 Days
175.6K
EPS TTM
$-0.19
Shares Outstanding
54.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the United States Department of Defense, Chemical Biological Medical Systems, Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the National Institute of Health. It has collaboration with Bristol-Myers Squibb for developing Valortim. The company is headquartered in Annapolis, Maryland.

52 Employees
Last Reported Date: 03/11/14

pharmathene inc (PIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $456.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $318.0K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $326.4K
Senior Vice President of Policy & Government ...
Total Annual Compensation: $294.4K
Compensation as of Fiscal Year 2013.

pharmathene inc (PIP) Key Developments

PharmAthene Presents New SparVax(R) Anthrax Vaccine Data at The FDA Medical Countermeasures Initiative Symposium

PharmAthene, Inc. announced that new data from its SparVax(R) anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD. In a presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax(R)) Provides Protection Equivalent to BioThrax(R) Against Lethal Challenge with Bacillus anthracis in New Zealand White Rabbits," Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented survival and toxin neutralization assay (TNA) results from a non-clinical anthrax aerosol challenge model. In this study, three groups of twenty New Zealand White (NZW) rabbits were vaccinated with SparVax(R) via intramuscular injection, on study days 0 and 28 at doses of 3, 9, or 27 micrograms. In addition, twenty animals were vaccinated with BioThrax(R), the currently-licensed anthrax vaccine. On the 70(th) day of the study, the NZW rabbits were challenged with a lethal dose of aerosolized anthrax spores. The results of the study demonstrated 100% survival (i.e. equivalent protection) of SparVax(R) compared to BioThrax(R). In addition, the preliminary TNA data showed that the antibody titers for SparVax(R) in this study were up to 2-fold higher than BioThrax(R), demonstrating that SparVax(R) is at least equivalent to BioThrax(R) as measured by either survival or TNA using the benchmark NZW rabbit model. PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority (BARDA).

PharmAthene Seeks Acquisitions

PharmAthene, Inc. (AMEX:PIP) has filed a shelf registration in the amount of $100 million. PharmAthene currently anticipates using any net proceeds to for general corporate purposes, which may include working capital, research and development expenses, general and administrative expenses, and capital expenditures. PharmAthene may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to own, although PharmAthene has no present definitive commitments or agreements for any such transactions on the date of this registration statement. Pending the application of such proceeds, PharmAthene may invest the proceeds in short-term, interest bearing, investment-grade marketable securities or money market obligations.

PharmAthene, Inc., Annual General Meeting, Jun 11, 2014

PharmAthene, Inc., Annual General Meeting, Jun 11, 2014., at 10:00 US Eastern Standard Time. Location: The offices of Dentons US LLP. Agenda: To elect up to 8 Directors to the Board of Directors to serve until 2015 Annual Meeting of Stockholders and until their successors have been elected and qualified; to ratify the selection by the audit committee of the board of Ernst & Young LLP as independent registered accounting firm for the fiscal year ending December 31, 2014; and to transact such other business as may properly come before the annual meeting and any adjournment or postponement of the annual meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.35 USD +0.06

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $76.47 USD -0.18
Bayer AG €99.63 EUR +1.09
Emergent Biosolutions Inc $22.44 USD -0.37
Protalix BioTherapeutics Inc 1,169 -13.00
View Industry Companies
 

Industry Analysis

PIP

Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit www.pharmathene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.